The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells

International Immunology

Volumn 27, Issue 3, 2015, Pages 153-160

  Chiurchiù, Valerio ^a,b   Lanuti, Mirko ^a,b   De Bardi, Marco ^a   Battistini, Luca ^a   Maccarrone, Mauro ^a,c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF TERAMO   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cannabinoid receptors; Immunoregulation; Innate immunity

Indexed keywords

4 (6 ISOPROPENYL 3 METHYL 2 CYCLOHEXENYL) 5 METHYLRESORCINOL; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 12; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CANNABIDIOL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXANE DERIVATIVE; CYTOKINE; GPR55 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; RESORCINOL DERIVATIVE; TRANSCRIPTOME;

ADAPTIVE IMMUNITY; ARTICLE; BLOOD; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; POLYCHROMATIC FLOW CYTOMETRY; PRIORITY JOURNAL; CELL CULTURE; CIRCULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

BLOOD CIRCULATION; CANNABIDIOL; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CELLS, CULTURED; CYCLOHEXANES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MONOCYTES; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; RESORCINOLS; TRANSCRIPTOME;

EID: 84929338552     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxu097     Document Type: Article

References (33)

1. Klein, T. W. 2005. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol. 5:400.
2. Viscomi, M. T., Oddi, S., Latini, L. et al. 2009. Selective CB2 receptor agonism protects central neurons from remote axotomyinduced apoptosis through the PI3K/Akt pathway. J. Neurosci. 29:4564.
3. Galve-Roperh, I., Chiurchiù, V., Díaz-Alonso, J., Bari, M., Guzmán, M. and Maccarrone, M. 2013. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog. Lipid Res. 52:633.
4. Sawzdargo, M., Nguyen, T., Lee, D. K. et al. 1999. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 64:193.
5. Gasperi, V., Dainese, E., Oddi, S., Sabatucci, A. and Maccarrone, M. 2013. GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors. Curr. Med. Chem. 20:64.
6. Ross, R. A. 2009. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30:156.
7. Sharir, H. and Abood, M. E. 2010. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 126:301.
8. Henstridge, C. M., Balenga, N. A., Kargl, J. et al. 2011. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol. Endocrinol. 25:1835.
9. Staton, P. C., Hatcher, J. P., Walker, D. J. et al. 2008. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139:225.
10. Schicho, R. and Storr, M. 2012. A potential role for GPR55 in gastrointestinal functions. Curr. Opin. Pharmacol. 12:653.
11. Whyte, L. S., Ryberg, E., Sims, N. A. et al. 2009. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl Acad. Sci. USA 106:16511.
12. Johns, D. G., Behm, D. J., Walker, D. J. et al. 2007. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152:825.
13. Hiley, C. R. and Kaup, S. S. 2007. GPR55 and the vascular receptors for cannabinoids. Br. J. Pharmacol. 152:559.
14. Ho, W. S. 2010. Angiogenesis: a new physiological role for N-arachidonoyl serine and GPR55? Br. J. Pharmacol. 160:1580.
15. Fonseca, B. M., Teixeira, N. A., Almada, M., Taylor, A. H., Konje, J. C. and Correia-da-Silva, G. 2011. Modulation of the novel cannabinoid receptor-GPR55-during rat fetoplacental development. Placenta 32:462.
16. Hu, G., Ren, G. and Shi, Y. 2011. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene 30:139.
17. Leyva-Illades, D. and Demorrow, S. 2013. Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management. Cancer Manag. Res. 5:147.
18. Schicho, R., Bashashati, M., Bawa, M. et al. 2011. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm. Bowel Dis. 17:1651.
19. Balenga, N. A., Aflaki, E., Kargl, J. et al. 2011. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 21:1452.
20. Cantarella, G., Scollo, M., Lempereur, L., Saccani-Jotti, G., Basile, F. and Bernardini, R. 2011. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem. Pharmacol. 82:380.
21. Cencioni, M. T., Chiurchiù, V., Catanzaro, G. et al. 2010. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5:e8688.
22. Chiurchiù, V., Cencioni, M. T., Bisicchia, E. et al. 2013. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann. Neurol. 73:626.
23. Chiurchiù, V., Lanuti, M., Catanzaro, G., Fezza, F., Rapino, C. and Maccarrone, M. 2014. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and antiinflammatory role of type-2 cannabinoid receptor. Atherosclerosis 233:55.
24. De Santis, G., Ferracin, M., Biondani, A. et al. 2010. Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J. Neuroimmunol. 226:165.
25. Souza-Fonseca-Guimaraes, F., Adib-Conquy, M. and Cavaillon, J. M. 2012. Natural killer (NK) cells in antibacterial innate immunity: angels or devils? Mol. Med. 18:270.
26. Kolaczkowska, E. and Kubes, P. 2013. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13:159.
27. Abraham, S. N. and St John, A. L. 2010. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 10:440.
28. Ziegler-Heitbrock, L., Ancuta, P., Crowe, S. et al. 2010. Nomenclature of monocytes and dendritic cells in blood. Blood 116:e74-e80.
29. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9:495.
30. Long, E. O., Kim, H. S., Liu, D., Peterson, M. E. and Rajagopalan, S. 2013. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31:227.
31. Waldhauer, I. and Steinle, A. 2008. NK cells and cancer immunosurveillance. Oncogene 27:5932.
32. Kaplar, B. L. 2013. The role of CB1 in immune modulation by cannabinoids. Pharmacol. Ther. 137:365.
33. Rom, S. and Persidsky, Y. 2013. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J. Neuroimmune Pharmacol. 8:608.